Free Trial

Arrowhead Pharmaceuticals (ARWR) Competitors

Arrowhead Pharmaceuticals logo
$31.51 +2.38 (+8.17%)
Closing price 09/18/2025 04:00 PM Eastern
Extended Trading
$31.79 +0.28 (+0.90%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARWR vs. SMMT, RDY, ASND, VTRS, QGEN, BBIO, ROIV, MRNA, ELAN, and VRNA

Should you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Moderna (MRNA), Elanco Animal Health (ELAN), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.

Arrowhead Pharmaceuticals vs. Its Competitors

Summit Therapeutics (NASDAQ:SMMT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Summit Therapeutics has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Summit Therapeutics presently has a consensus price target of $31.87, suggesting a potential upside of 65.71%. Arrowhead Pharmaceuticals has a consensus price target of $43.14, suggesting a potential upside of 36.92%. Given Summit Therapeutics' higher possible upside, research analysts plainly believe Summit Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Summit Therapeutics
4 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.56
Arrowhead Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summit Therapeutics has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Summit Therapeutics$700K20,407.15-$221.32M-$1.01-19.04
Arrowhead Pharmaceuticals$3.55M1,227.20-$599.49M-$1.28-24.62

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 26 mentions for Arrowhead Pharmaceuticals and 22 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.04 beat Arrowhead Pharmaceuticals' score of 0.40 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Summit Therapeutics
9 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Arrowhead Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arrowhead Pharmaceuticals' return on equity of -40.91% beat Summit Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Summit TherapeuticsN/A -208.64% -181.28%
Arrowhead Pharmaceuticals N/A -40.91%-11.62%

Summary

Summit Therapeutics and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARWR vs. The Competition

MetricArrowhead PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.03B$3.12B$5.78B$10.26B
Dividend YieldN/A2.37%5.74%4.64%
P/E Ratio-24.6221.3676.7426.98
Price / Sales1,227.20422.62512.93165.01
Price / CashN/A45.3237.1760.63
Price / Book20.469.6913.536.37
Net Income-$599.49M-$52.92M$3.29B$271.46M
7 Day Performance6.02%2.19%1.57%2.53%
1 Month Performance58.66%8.96%6.82%9.42%
1 Year Performance49.05%10.84%77.92%30.16%

Arrowhead Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARWR
Arrowhead Pharmaceuticals
4.1709 of 5 stars
$31.51
+8.2%
$43.14
+36.9%
+51.6%$4.03B$3.55M-24.62400Trending News
Insider Trade
Analyst Revision
Gap Up
SMMT
Summit Therapeutics
3.4089 of 5 stars
$18.94
flat
$33.79
+78.4%
-21.7%$14.07BN/A-18.75110Positive News
Analyst Forecast
RDY
Dr. Reddy's Laboratories
2.4587 of 5 stars
$14.64
-0.2%
$16.95
+15.8%
-6.0%$12.22B$3.81B22.1727,811Positive News
ASND
Ascendis Pharma A/S
2.9749 of 5 stars
$194.62
-0.5%
$244.36
+25.6%
+33.9%$11.91B$490.75M-37.721,017Positive News
VTRS
Viatris
1.4256 of 5 stars
$9.60
-3.6%
$10.40
+8.3%
-17.1%$11.19B$14.74B-3.3132,000
QGEN
QIAGEN
4.4768 of 5 stars
$45.39
+0.2%
$49.69
+9.5%
+3.0%$10.09B$1.98B26.825,765Positive News
BBIO
BridgeBio Pharma
4.4535 of 5 stars
$51.47
+0.5%
$63.94
+24.2%
+105.4%$9.84B$221.90M-12.58400
ROIV
Roivant Sciences
3.4421 of 5 stars
$13.95
-0.9%
$17.67
+26.6%
+25.8%$9.53B$29.05M-19.93860Trending News
Analyst Forecast
MRNA
Moderna
4.5452 of 5 stars
$23.88
+1.6%
$41.81
+75.1%
-63.6%$9.29B$3.24B-3.175,800Gap Up
ELAN
Elanco Animal Health
2.8915 of 5 stars
$18.63
+0.5%
$17.33
-6.9%
+30.5%$9.25B$4.44B21.669,000Positive News
VRNA
Verona Pharma PLC American Depositary Share
2.3471 of 5 stars
$106.37
-0.1%
$109.00
+2.5%
+263.5%$9.17B$42.28M-107.4430Positive News

Related Companies and Tools


This page (NASDAQ:ARWR) was last updated on 9/19/2025 by MarketBeat.com Staff
From Our Partners